The development of an effective synthetic route of lesinurad (RDEA594)

BACKGROUND: Lesinurad is a novel selective uric acid salt transport protein 1 (URAT1) inhibitor which is approved in the USA for the treatment of gout. However, there are some shortcomings among the reported synthetic routes, such as expensive materials, environmental pollution and poor yield. RESUL...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Qing, Zhao, Tong, Kang, Dongwei, Huang, Boshi, Zhan, Peng, Liu, Xinyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583131/
https://www.ncbi.nlm.nih.gov/pubmed/29086884
http://dx.doi.org/10.1186/s13065-017-0316-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583131/
https://www.ncbi.nlm.nih.gov/pubmed/29086884
http://dx.doi.org/10.1186/s13065-017-0316-y

Ejemplares similares